Comac Medical, a full-service contract research organization (CRO) based in Bulgaria, has announced major leadership changes alongside an international expansion drive, under the ownership of investment firm EdgeCap Partners.
The company, founded in 1997 in Sofia, said it has appointed Chris Smyth as chief executive, effective September 1. Mr Smyth, who is based in the UK, was previously president of ICON Biotech and held senior positions at IQVIA Biotech.
Comac Medical has also set up a new supervisory board chaired by Neil Ferguson, who has more than 35 years of experience in healthcare and clinical research services. Mr Ferguson previously held senior commercial roles at Syneos Health and Quintiles.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze